3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 13,738 | 10,603 |
売掛金 | 15,579 | 15,184 |
有価証券 | 3,500 | 555 |
商品及び製品 | 12,578 | 14,757 |
仕掛品 | 466 | 544 |
原材料及び貯蔵品 | 7,358 | 11,032 |
その他 | 2,922 | 5,463 |
貸倒引当金 | - | △94 |
流動資産合計 | 56,143 | 58,047 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 10,005 | 11,708 |
減価償却累計額 | △5,813 | △6,610 |
建物及び構築物(純額) | 4,192 | 5,097 |
機械装置及び運搬具 | 15,488 | 17,168 |
減価償却累計額 | △14,248 | △15,047 |
機械装置及び運搬具(純額) | 1,240 | 2,121 |
土地 | 4,249 | 4,255 |
建設仮勘定 | 1,101 | 6,550 |
その他 | 3,762 | 3,941 |
減価償却累計額 | △3,283 | △3,258 |
その他(純額) | 479 | 683 |
有形固定資産合計 | 11,263 | 18,709 |
無形固定資産 | | |
のれん | - | 4,361 |
その他 | 2,877 | 2,631 |
無形固定資産合計 | 2,877 | 6,993 |
投資その他の資産 | | |
投資有価証券 | 15,654 | 12,327 |
繰延税金資産 | 2,696 | 2,312 |
その他 | 2,127 | 2,162 |
貸倒引当金 | △17 | △17 |
投資その他の資産合計 | 20,461 | 16,784 |
固定資産合計 | 34,601 | 42,487 |
資産合計 | 90,745 | 100,534 |
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 4,060 | 6,411 |
電子記録債務 | 3,295 | 2,735 |
短期借入金 | 300 | 2,521 |
1年内返済予定の長期借入金 | 4,680 | 1,940 |
未払金 | 5,794 | 6,194 |
未払法人税等 | 2,896 | 173 |
賞与引当金 | 1,151 | 1,210 |
役員賞与引当金 | 74 | 73 |
その他 | 1,715 | 1,617 |
流動負債合計 | 23,968 | 22,879 |
固定負債 | | |
長期借入金 | 4,505 | 6,441 |
退職給付に係る負債 | - | 206 |
その他 | 341 | 1,811 |
固定負債合計 | 4,846 | 8,459 |
負債合計 | 28,815 | 31,339 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,197 | 1,197 |
資本剰余金 | 1,848 | - |
利益剰余金 | 56,372 | 59,545 |
自己株式 | △3,287 | △704 |
株主資本合計 | 56,130 | 60,039 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 4,790 | 4,853 |
為替換算調整勘定 | 424 | - |
退職給付に係る調整累計額 | 584 | 417 |
その他の包括利益累計額合計 | 5,799 | 5,271 |
非支配株主持分 | - | 3,885 |
純資産合計 | 61,930 | 69,195 |
負債純資産合計 | 90,745 | 100,534 |
E3579148860あすか製薬ホールディングス株式会社ASKA Pharmaceutical Holdings Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse488602025-03-31jppfs_cor:NonControllingInterestsMember488602024-04-012025-03-31jppfs_cor:NonControllingInterestsMember488602024-03-31jppfs_cor:NonControllingInterestsMember488602025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602024-04-012025-03-31tse-acedjpfr-48860:OverseaBusinessReportableSegmentsMember488602025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602025-03-31jppfs_cor:ShareholdersEquityMember488602025-03-31jppfs_cor:TreasuryStockMember488602025-03-31jppfs_cor:RetainedEarningsMember488602025-03-31jppfs_cor:CapitalSurplusMember488602025-03-31jppfs_cor:CapitalStockMember488602024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-04-012025-03-31jppfs_cor:ShareholdersEquityMember488602024-04-012025-03-31jppfs_cor:TreasuryStockMember488602024-04-012025-03-31jppfs_cor:RetainedEarningsMember488602024-04-012025-03-31jppfs_cor:CapitalSurplusMember488602024-04-012025-03-31jppfs_cor:CapitalStockMember488602024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602024-03-31jppfs_cor:ShareholdersEquityMember488602024-03-31jppfs_cor:TreasuryStockMember488602024-03-31jppfs_cor:RetainedEarningsMember488602024-03-31jppfs_cor:CapitalSurplusMember488602024-03-31jppfs_cor:CapitalStockMember488602025-05-12488602025-03-31488602024-04-012025-03-31488602024-03-31488602023-04-012024-03-31488602023-03-31488602023-03-31jppfs_cor:ShareholdersEquityMember488602023-03-31jppfs_cor:CapitalStockMember488602023-03-31jppfs_cor:CapitalSurplusMember488602023-03-31jppfs_cor:RetainedEarningsMember488602023-03-31jppfs_cor:TreasuryStockMember488602023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602023-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602023-04-012024-03-31jppfs_cor:ShareholdersEquityMember488602023-04-012024-03-31jppfs_cor:CapitalStockMember488602023-04-012024-03-31jppfs_cor:CapitalSurplusMember488602023-04-012024-03-31jppfs_cor:RetainedEarningsMember488602023-04-012024-03-31jppfs_cor:TreasuryStockMember488602023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember488602023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember488602023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember488602023-04-012024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember488602025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602023-04-012024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember488602025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602025-03-31jpcrp_cor:ReconcilingItemsMember488602024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602024-04-012025-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602024-04-012025-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember488602024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602024-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602024-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602024-03-31jpcrp_cor:ReconcilingItemsMember488602023-04-012024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember488602023-04-012024-03-31tse-acedjpfr-48860:PharmaceuticalBusinessReportableSegmentsMember488602023-04-012024-03-31tse-acedjpfr-48860:AnimalHealthBusinessReportableSegmentsMember488602023-04-012024-03-31jpcrp_cor:ReconcilingItemsMemberxbrli:pureiso4217:JPY